2-5 November 2020 | Live Digital
000s
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
3
Co-located events
2020 KEY SPEAKERS
World Immunotherapy Congress
Sessions You Can't Miss
Current state of combination therapies including PD-1 checkpoint inhibitors
•A cross sectional study of published clinical trials showed that more than 80% of combination trials including a PD-1 checkpoint inhibitor increased activity compared to PD-1 monotherapy in the same indication
•This remarkable success is largely due to additive effects of independent combination agents
• Clinical synergy is not common in PD-1 combination trials, and is more evident for chemo and targeted therapies than for evolving immune oncology agents
Emmett Schmidt, Associate Vice President, Clinical Research, Oncology, MSD
Management of toxicities associated with immuno-oncology therapies. Have we made progress?
• Current Clinical Practice Guidelines (e.g. ESMO and ASCO)
• Evolving treatment paradigms
• Explorative approaches: early recognition and detection of risk factors
Céline Adessi , Senior Director & Group Head of Oncology and Clinical Safety Science , Roche
Integrating complex biomarkers to predict response and understand resistance to cancer immunotherapy agents
• To date, no single biomarker has proven effective at predicting response to immunotherapy
• Integration of complex biomarker signatures will likely be required for accurate prediction
• Data from multi-parameter assays also inform on disease biology and mechanisms of resistance
Philip Beer , Visiting Scientist/Consultant Genomicist , Sanger Institute/NHS
There are two parts to the Festival of Biologics: three conferences covering Antibodies, Immunotherapy, Biosimilars and an exhibition featuring solutions for pharma and biotech.
Events
Contact us
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Natasha Evans
+44 (0)207 092 1212
Natasha.Evans@terrapinn.com
Organiser
